

**LEGISLATIVE SERVICES AGENCY
OFFICE OF FISCAL AND MANAGEMENT ANALYSIS**

200 W. Washington, Suite 301
Indianapolis, IN 46204
(317) 233-0696
<http://www.in.gov/legislative>

FISCAL IMPACT STATEMENT

LS 7222

BILL NUMBER: SB 383

NOTE PREPARED: Jan 5, 2005

BILL AMENDED:

SUBJECT: Chymopapain Use by Pain Management Physicians.

FIRST AUTHOR: Sen. Riegsecker

BILL STATUS: As Introduced

FIRST SPONSOR:

FUNDS AFFECTED: **GENERAL**
 DEDICATED
 FEDERAL

IMPACT: No Fiscal Impact

Summary of Legislation: This bill allows a physician who specializes in pain management to administer chymopapain. It removes language from a disclosure form that states that the manufacturing and distribution of chymopapain is banned by the federal Food and Drug Administration.

Effective Date: July 1, 2005.

Explanation of State Expenditures: *Background:* This bill adds physicians specializing in pain management to the list of specialists allowed to administer chymopapain. Current law allows only neurosurgeons and orthopedic surgeons to administer chymopapain.

Explanation of State Revenues:

Explanation of Local Expenditures:

Explanation of Local Revenues:

State Agencies Affected:

Local Agencies Affected:

Information Sources:

Fiscal Analyst: Kathy Norris, 317-234-1360.